Significant Ownership of Fairmount Funds Management LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Fairmount Funds Management LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Peter Harwin - Peter Harwin, Managing Member
- Manager location
- West Conshohocken, PA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Fairmount Funds Management LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Fairmount Funds Management LLC
Significant Ownership of Fairmount Funds Management LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | Common Stock, $0.0001 par value per share | 20% | $354,973,334 | +$93,745,067 | 14,069,494 | +36% | Fairmount Funds Management LLC | 05 Jun 2026 |
| GLTO | Galecto, Inc. | Common Stock, par value $0.00001 per share | 20% | $190,117,660 | +$181,455,120 | 8,713,000 | +2095% | Fairmount Funds Management LLC | 09 Feb 2026 |
| ORKA | ORUKA THERAPEUTICS, INC. | Common Stock, $0.001 par value per share | 20% | $997,807,627 | +$62,159,599 | 14,572,917 | +6.6% | Harwin Peter Evan | 01 Jul 2026 |
| CBIO | Crescent Biopharma, Inc. | Ordinary Shares, $0.001 par value | 17% | $118,843,344 | +$17,260,668 | 6,602,408 | +17% | Peter Harwin | 16 Jul 2026 |
| VRDN | Viridian Therapeutics, Inc.\DE | Common Stock, $0.01 par value per share | 14% | $239,105,020 | +$16,352,933 | 17,201,800 | +7.3% | Fairmount Funds Management LLC | 11 May 2026 |
| SYRE | SPYRE THERAPEUTICS, INC. | Common Stock, $0.0001 par value | 10% | $697,101,864 | +$46,907,483 | 9,667,201 | +7.2% | Peter Evan Harwin | 23 Jun 2026 |
| APGE | Apogee Therapeutics, Inc. | Common Stock, $0.00001 par value | 10% | $529,859,960 | +$3,409,683 | 6,808,789 | +0.65% | Peter Evan Harwin | 18 Jun 2026 |
| IKT | Inhibikase Therapeutics, Inc. | Common Stock, par value $0.001 per share | 9.9% | $24,922,202 | +$10,885,052 | 12,461,101 | +78% | Fairmount Funds Management LLC | 31 Dec 2025 |
| COGT | Cogent Biosciences, Inc. | Common Stock, $0.001 par value | 8.6% | $542,559,913 | -$31,973,650 | 15,356,918 | -5.6% | Fairmount Funds Management LLC | 31 Mar 2026 |
| DNTH | DIANTHUS THERAPEUTICS, INC. | Common Stock, $0.001 par value | 4.9% | $72,191,285 | -$64,524,950 | 2,139,635 | -47% | Fairmount Funds Management LLC | 21 Nov 2025 |
| ATXS | Astria Therapeutics, Inc. | Common Stock, par value $0.001 per share | 4% | $17,304,917 | -$25,421,673 | 2,377,049 | -59% | Fairmount Funds Management LLC | 14 Oct 2025 |
| ELVN | ENLIVEN THERAPEUTICS, INC. | Common Stock, par value $0.001 per share | 3.1% | $84,097,786 | -$84,104,856 | 1,855,644 | -50% | Fairmount Funds Management LLC | 31 Mar 2026 |
| ANAB | ANAPTYSBIO, INC. | Common Stock, par value $0.001 per share | 0% | $0 | -$34,599,719 | 0 | -100% | Fairmount Funds Management LLC | 31 Dec 2024 |
| KNSA | Kiniksa Pharmaceuticals International, plc | Class A Ordinary Shares, nominal value $0.000273235 per share | 0% | $0 | 0 | Fairmount Funds Management LLC | 31 Dec 2024 |
Schedules 13D/G Reported by Fairmount Funds Management LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.